## J Henricus Van Krieken

# List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/6273947/j-henricus-van-krieken-publications-by-year.pdf

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

138<br/>papers7,324<br/>citations36<br/>h-index84<br/>g-index167<br/>ext. papers8,819<br/>ext. citations4.2<br/>avg, IF5.11<br/>L-index

#	Paper	IF	Citations
138	e-Learning for Instruction and to Improve Reproducibility of Scoring Tumor-Stroma Ratio in Colon Carcinoma: Performance and Reproducibility Assessment in the UNITED Study. <i>JMIR Formative Research</i> , <b>2021</b> , 5, e19408	2.5	5
137	Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents. <i>Molecular Cancer Research</i> , <b>2021</b> , 19, 249-260	6.6	9
136	Daily practice in guideline adherence to adjuvant chemotherapy in stage III colon cancer and predictors of outcome. <i>European Journal of Surgical Oncology</i> , <b>2021</b> , 47, 2060-2068	3.6	O
135	Tumour-stroma ratio outperforms tumour budding as biomarker in colon cancer: a cohort study. <i>International Journal of Colorectal Disease</i> , <b>2021</b> , 36, 2729-2737	3	1
134	Memento for interprofessional learning. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2020</b> , 477, 755-756	5.1	O
133	Neoplastic cell percentage estimation in tissue samples for molecular oncology: recommendations from a modified Delphi study. <i>Histopathology</i> , <b>2019</b> , 75, 312-319	7.3	6
132	High frequency of inactivating tetraspanin mutations in diffuse large B-cell lymphoma at immune-privileged sites. <i>Blood</i> , <b>2019</b> , 134, 946-950	2.2	6
131	Uniform Noting for International Application of the Tumor-Stroma Ratio as an Easy Diagnostic Tool: Protocol for a Multicenter Prospective Cohort Study. <i>JMIR Research Protocols</i> , <b>2019</b> , 8, e13464	2	15
130	The tumour-stroma ratio in colon cancer: the biological role and its prognostic impact. <i>Histopathology</i> , <b>2018</b> , 73, 197-206	7.3	52
129	External Quality Assessment Identifies Training Needs to Determine the Neoplastic Cell Content for Biomarker Testing. <i>Journal of Molecular Diagnostics</i> , <b>2018</b> , 20, 455-464	5.1	13
128	RAS testing for colorectal cancer patients is reliable in European laboratories that pass external quality assessment. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2018</b> , 472, 717-725	5.1	5
127	Detection of EGFR Variants in Plasma: A Multilaboratory Comparison of a Real-Time PCR EGFR Mutation Test in Europe. <i>Journal of Molecular Diagnostics</i> , <b>2018</b> , 20, 483-494	5.1	19
126	Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy. <i>Leukemia</i> , <b>2018</b> , 32, 353-363	10.7	22
125	Scoring the tumor-stroma ratio in colon cancer: procedure and recommendations. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2018</b> , 473, 405-412	5.1	62
124	Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma. <i>Neoplasia</i> , <b>2018</b> , 20, 574-593	6.4	30
123	A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. <i>Modern Pathology</i> , <b>2018</b> , 31, 1770-1786	9.8	428
122	Accreditation, setting and experience as indicators to assure quality in oncology biomarker testing laboratories. <i>British Journal of Cancer</i> , <b>2018</b> , 119, 605-614	8.7	15

### (2016-2017)

121	Recurrent mutations in genes involved in nuclear factor- <b>B</b> signalling in nodal marginal zone lymphoma-diagnostic and therapeutic implications. <i>Histopathology</i> , <b>2017</b> , 70, 174-184	7.3	15	
120	AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma. <i>American Journal of Pathology</i> , <b>2017</b> , 187, 1700-1716	5.8	34	
119	Hepatitis C virus positive diffuse large B-cell lymphomas have distinct molecular features and lack BCL2 translocations. <i>British Journal of Cancer</i> , <b>2017</b> , 117, 1685-1688	8.7	9	
118	Novel developments in the pathogenesis and diagnosis of extranodal marginal zone lymphoma. <i>Journal of Hematopathology</i> , <b>2017</b> , 10, 91-107	0.4	38	
117	New developments in the pathology of malignant lymphoma: a review of the literature published from May to August 2017. <i>Journal of Hematopathology</i> , <b>2017</b> , 10, 65-73	0.4	3	
116	High mRNA expression of splice variant SYK short correlates with hepatic disease progression in chemonaive lymph node negative colon cancer patients. <i>PLoS ONE</i> , <b>2017</b> , 12, e0185607	3.7	6	
115	Unraveling genetic predisposition to familial or early onset gastric cancer using germline whole-exome sequencing. <i>European Journal of Human Genetics</i> , <b>2017</b> , 25, 1246-1252	5.3	27	
114	New developments in the pathology of malignant lymphoma: a review of the literature published from January to April 2017. <i>Journal of Hematopathology</i> , <b>2017</b> , 10, 25-33	0.4	1	
113	RAS mutation prevalence among patients with metastatic colorectal cancer: a meta-analysis of real-world data. <i>Biomarkers in Medicine</i> , <b>2017</b> , 11, 751-760	2.3	21	
112	Pathways towards indolent B-cell lymphoma - Etiology and therapeutic strategies. <i>Blood Reviews</i> , <b>2017</b> , 31, 426-435	11.1	6	
111	Multispectral imaging for highly accurate analysis of tumour-infiltrating lymphocytes in primary melanoma. <i>Histopathology</i> , <b>2017</b> , 70, 643-649	7.3	12	
110	Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma. <i>Leukemia</i> , <b>2017</b> , 31, 625-636	10.7	38	
109	Integration of next-generation sequencing in clinical diagnostic molecular pathology laboratories for analysis of solid tumours; an expert opinion on behalf of IQN Path ASBL. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2017</b> , 470, 5-20	5.1	62	
108	New developments in the pathology of malignant lymphoma. A review of the literature published from September-August 2017. <i>Journal of Hematopathology</i> , <b>2017</b> , 10, 117-127	0.4	2	
107	Direct inhibition of STAT signaling by platinum drugs contributes to their anti-cancer activity. <i>Oncotarget</i> , <b>2017</b> , 8, 54434-54443	3.3	12	
106	A subset of low-grade B cell lymphomas with a follicular growth pattern but without a translocation shows features suggestive of nodal marginal zone lymphoma. <i>Journal of Hematopathology</i> , <b>2016</b> , 9, 3-8	0.4	7	
105	Histopathological, Molecular, and Genetic Profile of Hereditary Diffuse Gastric Cancer: Current Knowledge and Challenges for the Future. <i>Advances in Experimental Medicine and Biology</i> , <b>2016</b> , 908, 371-91	3.6	34	
104	New developments in the pathology of malignant lymphoma: a review of the literature published from June-August 2016. <i>Journal of Hematopathology</i> , <b>2016</b> , 9, 129-134	0.4	1	

103	How we do: optimizing bone marrow biopsy logistics for sign-out within 2days. <i>Journal of Hematopathology</i> , <b>2016</b> , 9, 67-71	0.4	2
102	New developments in the pathology of malignant lymphoma. A review of the literature published from September 2015-December 2015. <i>Journal of Hematopathology</i> , <b>2016</b> , 9, 19-27	0.4	3
101	Clinical features of patients with nodal marginal zone lymphoma compared to follicular lymphoma: similar presentation, but differences in prognostic factors and rate of transformation. <i>Leukemia and Lymphoma</i> , <b>2016</b> , 57, 1649-56	1.9	12
100	RAS testing in metastatic colorectal cancer: advances in Europe. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2016</b> , 468, 383-96	5.1	23
99	A 20-year population-based study on the epidemiology, clinical features, treatment, and outcome of nodular lymphocyte predominant Hodgkin lymphoma. <i>Annals of Hematology</i> , <b>2016</b> , 95, 417-23	3	13
98	Three Rounds of External Quality Assessment in France to Evaluate the Performance of 28 Platforms for Multiparametric Molecular Testing in Metastatic Colorectal and Non-Small Cell Lung Cancer. <i>Journal of Molecular Diagnostics</i> , <b>2016</b> , 18, 205-14	5.1	18
97	Tetraspanin CD37 protects against the development of B cell lymphoma. <i>Journal of Clinical Investigation</i> , <b>2016</b> , 126, 653-66	15.9	32
96	p63 expression confers significantly better survival outcomes in high-risk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function. <i>Aging</i> , <b>2016</b> , 8, 345-65	5.6	17
95	RelA NF- <b>B</b> subunit activation as a therapeutic target in diffuse large B-cell lymphoma. <i>Aging</i> , <b>2016</b> , 8, 3321-3340	5.6	20
94	Improving hospital care for patients with non-Hodgkin@lymphomas <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 6593-6593	2.2	
93	Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma. <i>Oncotarget</i> , <b>2016</b> , 7, 2401-16	3.3	68
92	ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. <i>Annals of Oncology</i> , <b>2016</b> , 27, 1386-422	10.3	1683
91	Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell Lymphoma. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 3593-605	12.9	39
90	The Role of Dectin-2 for Host Defense Against Disseminated Candidiasis. <i>Journal of Interferon and Cytokine Research</i> , <b>2016</b> , 36, 267-76	3.5	33
89	T-cell Landscape in a Primary Melanoma Predicts the Survival of Patients with Metastatic Disease after Their Treatment with Dendritic Cell Vaccines. <i>Cancer Research</i> , <b>2016</b> , 76, 3496-506	10.1	27
88	New developments in the pathology of malignant lymphoma. A review of the literature published from January-April 2016. <i>Journal of Hematopathology</i> , <b>2016</b> , 9, 73-83	0.4	2
87	Gastric cancer in three relatives of a patient with a biallelic IL12RB1 mutation. <i>Familial Cancer</i> , <b>2015</b> , 14, 89-94	3	10
86	Epstein-Barr virus in inflammatory bowel disease: the spectrum of intestinal lymphoproliferative disorders. <i>Journal of Crohn</i> and <i>Colitis</i> , <b>2015</b> , 9, 398-403	1.5	51

#### (2015-2015)

85	Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. <i>Journal of Medical Genetics</i> , <b>2015</b> , 52, 361-74	5.8	385
84	Trends in quality of non-Hodgkin@lymphoma care: is it getting better?. <i>Annals of Hematology</i> , <b>2015</b> , 94, 1195-203	3	3
83	A germline homozygous mutation in the base-excision repair gene NTHL1 causes adenomatous polyposis and colorectal cancer. <i>Nature Genetics</i> , <b>2015</b> , 47, 668-71	36.3	229
82	New developments in the pathology of malignant lymphoma: a review of the literature published from October 2014-December 2014. <i>Journal of Hematopathology</i> , <b>2015</b> , 8, 21-29	0.4	O
81	New developments in the pathology of malignant lymphoma: a review of literature published from January 2015 to April 2015. <i>Journal of Hematopathology</i> , <b>2015</b> , 8, 71-79	0.4	1
80	Variation in guideline adherence in non-Hodgkin@lymphoma care: impact of patient and hospital characteristics. <i>BMC Cancer</i> , <b>2015</b> , 15, 578	4.8	5
79	Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. <i>Modern Pathology</i> , <b>2015</b> , 28, 1555-73	9.8	40
78	Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy. <i>Modern Pathology</i> , <b>2015</b> , 28, 1297-314	9.8	18
77	The homogeneous mutation status of a 22 gene panel justifies the use of serial sections of colorectal cancer tissue for external quality assessment. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2015</b> , 467, 273-8	5.1	9
76	Immunoglobulin rearrangement analysis from multiple lesions in the same patient using next-generation sequencing. <i>Histopathology</i> , <b>2015</b> , 67, 843-58	7.3	5
75	Evaluation of NF- <b>B</b> subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions. <i>Modern Pathology</i> , <b>2015</b> , 28, 1202-13	9.8	15
74	Lymphocytic variant hypereosinophilic syndrome progressing to angioimmunoblastic T-cell lymphoma. <i>Leukemia and Lymphoma</i> , <b>2015</b> , 56, 1891-4	1.9	13
73	External quality assessment unravels interlaboratory differences in quality of RAS testing for anti-EGFR therapy in colorectal cancer. <i>Oncologist</i> , <b>2015</b> , 20, 257-62	5.7	35
7 <del>2</del>	Identification of IG-clonality status as a pre-treatment predictor for mortality in patients with immunodeficiency-associated Epstein-Barr virus-related lymphoproliferative disorders. <i>Haematologica</i> , <b>2015</b> , 100, e152-4	6.6	O
71	Reduced Circumferential Resection Margin Involvement in Rectal Cancer Surgery: Results of the Dutch Surgical Colorectal Audit. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2015</b> , 13, 1111-9	7.3	15
70	Panitumumab Use in Metastatic Colorectal Cancer and Patterns of KRAS Testing: Results from a Europe-Wide Physician Survey and Medical Records Review. <i>PLoS ONE</i> , <b>2015</b> , 10, e0140717	3.7	9
69	Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma. <i>Oncotarget</i> , <b>2015</b> , 6, 5597-614	3.3	53
68	New developments in the pathology of malignant lymphoma: a review of the literature published from May 2015-September 2015. <i>Journal of Hematopathology</i> , <b>2015</b> , 8, 225-234	0.4	2

67	Immunohistochemical differentiation between follicular lymphoma and nodal marginal zone lymphomacombined performance of multiple markers. <i>Haematologica</i> , <b>2015</b> , 100, e358-60	6.6	16
66	Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries. <i>Oncotarget</i> , <b>2015</b> , 6, 5615-33	3.3	54
65	RAS testing in metastatic colorectal cancer: excellent reproducibility amongst 17 Dutch pathology centers. <i>Oncotarget</i> , <b>2015</b> , 6, 15681-9	3.3	12
64	Prognostic impact of c-Rel nuclear expression and REL amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma. <i>Oncotarget</i> , <b>2015</b> , 6, 23157-80	3.3	32
63	Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphomais it necessary?. <i>Oncotarget</i> , <b>2015</b> , 6, 13933-45	3.3	29
62	Awareness of KRAS testing by oncologists and panitumumab use in colorectal cancer patients: A European survey <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 547-547	2.2	
61	New developments in the pathology of malignant lymphoma. A review of the literature published from August 2013 to December 2013. <i>Journal of Hematopathology</i> , <b>2014</b> , 7, 15-25	0.4	
60	Sequential immunohistochemistry: a promising new tool for the pathology laboratory. <i>Histopathology</i> , <b>2014</b> , 65, 651-7	7.3	34
59	Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 2338-49	12.9	96
58	HNF4A immunohistochemistry facilitates distinction between primary and metastatic breast and gastric carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2014</b> , 464, 673-9	5.1	18
57	Limited diagnostic value of microsatellite instability associated pathology features in colorectal cancer. <i>Familial Cancer</i> , <b>2014</b> , 13, 351-9	3	3
56	Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. <i>Modern Pathology</i> , <b>2014</b> , 27, 958-71	9.8	99
55	Clinical implications of phosphorylated STAT3 expression in De Novo diffuse large B-cell lymphoma. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 5113-23	12.9	52
54	Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program. <i>Cancer</i> , <b>2014</b> , 120, 1818-29	6.4	28
53	Higher quality of molecular testing, an unfulfilled priority: Results from external quality assessment for KRAS mutation testing in colorectal cancer. <i>Journal of Molecular Diagnostics</i> , <b>2014</b> , 16, 371-7	5.1	20
52	New developments in the pathology of malignant lymphoma. A review of the literature published from JuneAugust 2014. <i>Journal of Hematopathology</i> , <b>2014</b> , 7, 103-108	0.4	
51	Evaluation of a panel of expert pathologists: review of the diagnosis and histological classification of Hodgkin and non-Hodgkin lymphomas in a population-based cancer registry. <i>Leukemia and Lymphoma</i> , <b>2014</b> , 55, 1018-22	1.9	10
50	Role of Dectin-2 for host defense against systemic infection with Candida glabrata. <i>Infection and Immunity</i> , <b>2014</b> , 82, 1064-73	3.7	80

49	Neoadjuvant sorafenib treatment of clear cell renal cell carcinoma and release of circulating tumor fragments. <i>Neoplasia</i> , <b>2014</b> , 16, 221-8	6.4	9
48	The ileo neo rectal anastomosis: long-term results of surgical innovation in patients after ulcerative colitis and familial adenomatous polyposis. <i>International Journal of Colorectal Disease</i> , <b>2013</b> , 28, 111-8	3	5
47	Trends in incidence, therapy and outcome of localized nodal and extranodal marginal zone lymphomas: declining incidence and inferior outcome for gastrointestinal sites. <i>Leukemia and Lymphoma</i> , <b>2013</b> , 54, 1891-7	1.9	15
46	Guideline on the requirements of external quality assessment programs in molecular pathology. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2013</b> , 462, 27-37	5.1	59
45	KRAS mutation analysis on low percentage of colon cancer cells: the importance of quality assurance. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2013</b> , 462, 39-46	5.1	26
44	MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. <i>Blood</i> , <b>2013</b> , 121, 4021-31;	2.2	473
43	CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. <i>Blood</i> , <b>2013</b> , 121, 2715-24	2.2	157
42	The evaluation of colon biopsies using virtual microscopy is reliable. <i>Histopathology</i> , <b>2013</b> , 63, 114-21	7.3	20
41	Diagnosing and classifying malignant lymphomas is improved by referring cases to a panel of expert pathologists. <i>Journal of Hematopathology</i> , <b>2013</b> , 6, 179-185	0.4	1
40	Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study. <i>Haematologica</i> , <b>2013</b> , 98, 255-63	6.6	125
39	Recognizing nodal marginal zone lymphoma: recent advances and pitfalls. A systematic review. <i>Haematologica</i> , <b>2013</b> , 98, 1003-13	6.6	66
38	T(14;18)(q32;q21) involving MALT1 and IGH genes occurs in extranodal diffuse large B-cell lymphomas of the breast and testis. <i>Modern Pathology</i> , <b>2013</b> , 26, 421-7	9.8	16
37	European consensus conference for external quality assessment in molecular pathology. <i>Annals of Oncology</i> , <b>2013</b> , 24, 1958-63	10.3	32
36	Undertreatment of patients with localized extranodal compared with nodal diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , <b>2013</b> , 54, 1698-705	1.9	4
35	Single nucleotide variation in the TP53 3Quntranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program. <i>Blood</i> , <b>2013</b> , 121, 4529-40	2.2	35
34	Centralised multidisciplinary re-evaluation of diagnostic procedures in patients with newly diagnosed Hodgkin lymphoma. <i>Annals of Oncology</i> , <b>2012</b> , 23, 2676-2681	10.3	10
33	Higher cytoplasmic and nuclear poly(ADP-ribose) polymerase expression in familial than in sporadic breast cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2012</b> , 461, 425-31	5.1	4
32	Application of microfluidic technology to the BIOMED-2 protocol for detection of B-cell clonality. Journal of Molecular Diagnostics, <b>2012</b> , 14, 30-7	5.1	19

31	Do pre-analytical parameters explain KRAS test sensitivity disparities?. <i>Journal of Molecular Diagnostics</i> , <b>2012</b> , 14, 631-3; author reply 632-3	5.1	1
30	Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. <i>Leukemia</i> ,	10.7	251
29	New developments in the pathology of malignant lymphoma. A review of the literature published from January 2012 July 2012. <i>Journal of Hematopathology</i> , <b>2012</b> , 5, 149-157	0.4	
28	Familial gastric cancer: guidelines for diagnosis, treatment and periodic surveillance. <i>Familial Cancer</i> , <b>2012</b> , 11, 363-9	3	61
27	Clinical and pathological features of testicular diffuse large B-cell lymphoma: a heterogeneous disease. <i>Leukemia and Lymphoma</i> , <b>2012</b> , 53, 242-6	1.9	11
26	Molecular pathogenesis and histologic and clinical features of extranodal marginal zone lymphomas of mucosa-associated lymphoid tissue type. <i>Leukemia and Lymphoma</i> , <b>2012</b> , 53, 1032-45	1.9	14
25	Implementation of formalin-fixed, paraffin-embedded cell line pellets as high-quality process controls in quality assessment programs for KRAS mutation analysis. <i>Journal of Molecular Diagnostics</i> , <b>2012</b> , 14, 187-91	5.1	11
24	CDH1-related hereditary diffuse gastric cancer syndrome: clinical variations and implications for counseling. <i>International Journal of Cancer</i> , <b>2012</b> , 131, 367-76	7.5	90
23	Psychological distress in newly diagnosed colorectal cancer patients following microsatellite instability testing for Lynch syndrome on the pathologist@initiative. <i>Familial Cancer</i> , <b>2012</b> , 11, 259-67	3	14
22	A practical approach to diagnostic Ig/TCR clonality evaluation in clinical pathology. <i>Journal of Hematopathology</i> , <b>2012</b> , 5, 17-25	0.4	9
21	Clonality testing: teamwork by pathologist and molecular biologist. <i>Journal of Hematopathology</i> , <b>2012</b> , 5, 3-5	0.4	
20	The times have changed: molecular pathology is here to stay. A commentary on: analytical performance of a PCR assay for the detection of KRAS mutations (codons 12/13 and 61) in formalin-fixed paraffin-embedded tissue samples of colorectal carcinoma, by Lee et al. In this issue.	5.1	2
19	Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. <i>Lancet Oncology, The</i> , <b>2011</b> , 12, 49-55	21.7	197
18	Preparing pathology for personalized medicine: possibilities for improvement of the pre-analytical phase. <i>Histopathology</i> , <b>2011</b> , 59, 1-7	7.3	31
17	Inter-observer variation in the histological diagnosis of polyps in colorectal cancer screening. <i>Histopathology</i> , <b>2011</b> , 58, 974-81	7-3	39
16	Cancer risk in patients with Noonan syndrome carrying a PTPN11 mutation. <i>European Journal of Human Genetics</i> , <b>2011</b> , 19, 870-4	5.3	113
15	KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. <i>British Journal of Cancer</i> , <b>2011</b> , 104, 1020-6	8.7	226
14	Variation in lymph node evaluation in rectal cancer: a Dutch nationwide population-based study. <i>Annals of Surgical Oncology</i> , <b>2011</b> , 18, 386-95	3.1	21

#### LIST OF PUBLICATIONS

13	Mutation analysis of KRAS prior to targeted therapy in colorectal cancer: development and evaluation of quality by a European external quality assessment scheme. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2011</b> , 459, 155-60	5.1	16
12	New developments in the pathology of malignant lymphoma: a review of the literature published from November 2010[January 2011. <i>Journal of Hematopathology</i> , <b>2011</b> , 4, 31-43	0.4	
11	High prevalence of adverse prognostic genetic aberrations and unmutated IGHV genes in small lymphocytic lymphoma as compared to chronic lymphocytic leukemia. <i>Journal of Hematopathology</i> , <b>2011</b> , 4, 189-197	0.4	1
10	New developments in the pathology of malignant lymphoma. A review of the literature published from February 2011 to August 2011. <i>Journal of Hematopathology</i> , <b>2011</b> , 4, 135-144	0.4	
9	Recurrence and variability of germline EPCAM deletions in Lynch syndrome. <i>Human Mutation</i> , <b>2011</b> , 32, 407-14	4.7	111
8	Identification of candidate predisposing copy number variants in familial and early-onset colorectal cancer patients. <i>International Journal of Cancer</i> , <b>2011</b> , 129, 1635-42	7.5	56
7	Cellular angiofibroma: analysis of 25 cases emphasizing its relationship to spindle cell lipoma and mammary-type myofibroblastoma. <i>Modern Pathology</i> , <b>2011</b> , 24, 82-9	9.8	123
6	External quality assessment for KRAS testing is needed: setup of a European program and report of the first joined regional quality assessment rounds. <i>Oncologist</i> , <b>2011</b> , 16, 467-78	5.7	75
5	Large variation between hospitals and pathology laboratories in lymph node evaluation in colon cancer and its impact on survival, a nationwide population-based study in the Netherlands. <i>Annals of Oncology</i> , <b>2011</b> , 22, 110-117	10.3	30
4	Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice. <i>Journal of Clinical Investigation</i> , <b>2011</b> , 121, 3100-8	15.9	210
3	Overlap, common features, and essential differences in pediatric granulomatous inflammatory bowel disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , <b>2010</b> , 51, 690-7	2.8	36
2	New developments in the pathology of malignant lymphoma. A review of the literature published from August 2010Dctober 2010. <i>Journal of Hematopathology</i> , <b>2010</b> , 3, 167-174	0.4	
1	Use of RNA Electroporated DC for Activation of LRH-1 Specific Cytotoxic T Lymphocytes in the Treatment of Lymphoid Malignancies <i>Blood</i> , <b>2006</b> , 108, 138-138	2.2	